About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die... http://www.eirx.com/index.html
There will be a lot of shares shifted over the next few days I would think, a good time to buy more or just sit tight and wait for a nice blue colour by the end of the week.
kim
Drug discovery company Eirx therapeutics, which is developing therapies for cancer and has just raised 1.2 million through a placing, eased 0.02p to 0.026p amid speculation a deal with a Danish company was imminent.
I don't know anything about Danish drug companies other than the company ZGene, which is developing cancer drugs - could be them, but have no idea really. That should not detract from the sp long term.
kim
Lets not forget why we invested in ERX I topped up today.
EiRx passed an important milestone in August 2005 with the filing of the company's first patents covering distinct chemical compounds that may be useful in the treatment of cancer. These drug candidates were identified using the Company's EnPADTM screening technology, which enables the discovery of compounds that specifically target the cell survival pathways relied upon by tumours for continued growth and viability. In January of 2006, the Company announced a second patent application describing another series of compounds identified with the use of EnPADTM. Both these patent applications describe series of novel compounds that selectively kill colorectal and breast cancer cells in vitro.
With the benefit of the anticipated new funds I am confident that EiRx can progress to secure proof of concept for the leading compounds in our pipeline, creating a solid basis for future partnering activities.
Hope so-just back from 2 weeks in Majorca-not much contact with the market so very glad to be out of the turmoil! glad to see erx and hml are holding up not so impressed with PCM without the bid tv deal how much of a business do they have?? not much I can salvage so will have to hold on-also a bit sick to have sold 30000 TTC shares before going away and missed out on the takeover when will I learn not to be hasty!!
Topped up today the sp could move very fast with some news that could appear at any time.
There could be strong news flow as three or four compounds move along the drug discovery cycle.
Large Pharma competition pushing licensing activity to earlier stages of development
Focus on cancer is lucrative in terms of both licensing deals and M&A activity.
Also big Pharma can look to acquire cancer companies for access to product pipeline.
Discussion with major pharmas can be convoluted and a number of such discussions to secure out licensing agreements are on going.
Thank you so much driver-what an exciting find.quite apart from holding the shares I very much hope the company has it's breakthrough soon. The Chairman sounded a sincere man quite a change these days!!
I can reinforce the message delivered by driver, the company are at a fairly advanced stage of negotiations with more than one option on the table. Coupled with this you should also expect to see a change of house broker